MarketBeat
08 Aug 2026, 07:04 UTC · 8w ago
Evolent Health Q2 Earnings Call Highlights
Impact · against what's priced in
EVH is a positive catalyst due to a significant new oncology contract and raised revenue guidance, though marginal EBITDA narrowing and rising medical expense ratios provide some friction. The $300 million annualized revenue addition represents a tangible growth acceleration beyond current expectations.
- EVH+0.60
No priced-in read yet
- In context
The new oncology Performance Suite agreement is expected to generate $300 million in annualized revenue by December 2026, alongside raised full-year revenue guidance to $2.6B-$2.7B. While adjusted EBITDA guidance was slightly narrowed and the Q2 medical expense ratio rose to 95%, the aggressive 2027 growth target of >25% indicates strong scalability.
Search tags
